Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of valproic acid, all-trans retinoic acid and their combination plus pegfilgrastim in younger patients with newly diagnosed acute myeloid leukemia
2004-004321-95Phase 2Completed
- Sponsor
- Ulm University
- Start
- Apr 2005
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of valproic acid, tretinoin and pegfilgrastim in acute myeloid leukemia (AML) (3 arms), sponsored by Ulm University. Primary endpoints: Complete remission rate after induction therapy and Safety of valproic acid, all-trans retinoic acid, and their combination during induction and consolidation. Started Apr 2005; status: completed.
02
Drugs
valproic acidtretinoinpegfilgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2004-004321-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004321-95.